Q-omics provides the consensus-scored MUTYH profile across patient tissues and cancer cell-line models. MUTYH expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MUTYH is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, MUTYH RNA expression shows 18,825 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where MUTYH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUTYH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUTYH survival associations across molecular data types. MUTYH RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUTYH RNA expression–survival associations across cancer types. High MUTYH expression shows unfavorable associations in KIRC, LIHC, ACC, LGG and PRAD, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MUTYH RNA expression.
This table summarizes MUTYH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MUTYH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUTYH shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, LIHC, BLCA and STAD. The COAD box plot shows higher MUTYH RNA expression in tumor versus normal tissue (log2 FC = +0.882, t-test p < 0.001).
This table shows molecular features associated with MUTYH in patient tissues and cancer cell lines. In patient samples, MUTYH shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MUTYH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
